Bluebird Bio Stock Performance
| BLUE Stock | USD 0.35 0.05 16.67% |
The firm shows a Beta (market volatility) of 1.92, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bluebird Bio will likely underperform. At this point, Bluebird bio has a negative expected return of -0.78%. Please make sure to confirm Bluebird Bio's skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Bluebird bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bluebird bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Last Split Factor 1544:1000 | Last Split Date 2021-11-05 |
1 | Bluebird Q2 Earnings Snapshot | 09/27/2024 |
2 | bluebird bio Now Covered by Analysts at StockNews.com | 10/09/2024 |
3 | BLUE SUEDE HOSPITALITY GROUP NAMES SHADE GROUP AS AGENCY OF RECORD | 11/04/2024 |
4 | bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society ... | 11/05/2024 |
5 | bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call | 11/06/2024 |
6 | After Plunging -22.76 percent in 4 Weeks, Heres Why the Trend Might Reverse for Bluebird | 11/08/2024 |
7 | bluebird bio Q3 2024 Earnings Preview | 11/13/2024 |
8 | Earnings call Bluebird bio sees patient growth, aims for 2025 breakeven | 11/14/2024 |
9 | bluebird bio, Inc.s Revenues Are Not Doing Enough For Some Investors | 11/15/2024 |
10 | Bluebird Bios SWOT analysis gene therapy firm faces cash crunch amid launch | 11/21/2024 |
| Begin Period Cash Flow | 158.4 M |
Bluebird |
Bluebird Bio Relative Risk vs. Return Landscape
If you would invest 63.00 in Bluebird bio on August 27, 2024 and sell it today you would lose (28.00) from holding Bluebird bio or give up 44.44% of portfolio value over 90 days. Bluebird bio is currently does not generate positive expected returns and assumes 5.2143% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Bluebird, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bluebird Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bluebird Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bluebird bio, and traders can use it to determine the average amount a Bluebird Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1494
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BLUE |
Estimated Market Risk
| 5.21 actual daily | 46 54% of assets are more volatile |
Expected Return
| -0.78 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bluebird Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bluebird Bio by adding Bluebird Bio to a well-diversified portfolio.
Bluebird Bio Fundamentals Growth
Bluebird Stock prices reflect investors' perceptions of the future prospects and financial health of Bluebird Bio, and Bluebird Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bluebird Stock performance.
| Return On Equity | -1.87 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (5.49) % | ||||
| Current Valuation | 365.83 M | ||||
| Shares Outstanding | 194.44 M | ||||
| Price To Earning | (19.32) X | ||||
| Price To Book | 0.73 X | ||||
| Price To Sales | 1.24 X | ||||
| Revenue | 29.5 M | ||||
| Gross Profit | (247.24 M) | ||||
| EBITDA | (302.11 M) | ||||
| Net Income | (211.91 M) | ||||
| Cash And Equivalents | 132.51 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 424.62 M | ||||
| Debt To Equity | 1.63 % | ||||
| Current Ratio | 1.12 X | ||||
| Book Value Per Share | 1.01 X | ||||
| Cash Flow From Operations | (235.05 M) | ||||
| Earnings Per Share | (1.80) X | ||||
| Market Capitalization | 68.07 M | ||||
| Total Asset | 619.16 M | ||||
| Retained Earnings | (4.26 B) | ||||
| Working Capital | 81.57 M | ||||
| Current Asset | 523.97 M | ||||
| Current Liabilities | 40.37 M | ||||
About Bluebird Bio Performance
By analyzing Bluebird Bio's fundamental ratios, stakeholders can gain valuable insights into Bluebird Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bluebird Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bluebird Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 249.51 | 261.99 | |
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.58) | (0.61) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (1.09) | (1.03) |
Things to note about Bluebird bio performance evaluation
Checking the ongoing alerts about Bluebird Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bluebird bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bluebird bio generated a negative expected return over the last 90 days | |
| Bluebird bio has high historical volatility and very poor performance | |
| Bluebird bio has some characteristics of a very speculative penny stock | |
| Bluebird bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 29.5 M. Net Loss for the year was (211.91 M) with loss before overhead, payroll, taxes, and interest of (247.24 M). | |
| Bluebird bio currently holds about 132.51 M in cash with (235.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Bluebird bio has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Bluebird Bios SWOT analysis gene therapy firm faces cash crunch amid launch |
- Analyzing Bluebird Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bluebird Bio's stock is overvalued or undervalued compared to its peers.
- Examining Bluebird Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bluebird Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bluebird Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bluebird Bio's stock. These opinions can provide insight into Bluebird Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bluebird Stock analysis
When running Bluebird Bio's price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |